Description
BMS-754807 is an inhibitor of the insulin receptor (InsR) and IGF-1R that exhibits anticancer chemotherapeutic activity. BMS-754807 enhances the efficacy of other co-administered chemotherapeutics, decreasing levels of activated Akt, increasing cleavage of PARP and caspase 3, and inhibiting proliferation in pancreatic ductal adenocarcinoma cells and breast cancer cells in vitro and growth of tumor xenografts in vivo.